Current guidelines and expert opinion recommend this strategy as the main treatment choice in most of the more common subtypes, excluding ALCL ALK-positive, extranodal NK/T-cell lymphoma and Adult T-cell Leukemia/Lymphoma (ATLL) (2, 35). This evidence concerns the gene ALK and adult T-cell leukemia/lymphoma.